Bioventus Q4 net loss $44.9M; FY22 net loss $213.4M; removes $350M CartiHeal liabilities

Bioventus Inc.

Net sales Q4 $125.8M (-3.5% YoY); Pain Treatments down 25.4% on higher rebate claims.
FY22 net loss $213.4M vs $9.6M income in 2021; includes $189.2M non-cash impairment.
Adjusted EBITDA Q4 $15.2M vs $28.5M; FY22 $66.3M vs $80.8M.
Settlement on Feb 28, 2023 removed $350M of CartiHeal liabilities; credit agreement amended for covenant relief.
Cash $31.8M, debt $418.1M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bioventus Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 31, 2023 , Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-010022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.